Skip to main content
SpringerLink
Log in
Book cover

Endocrine Surgery pp 85–95Cite as

Thyrotoxicosis and Thyroiditis: Causes, Investigation, and Management

  • Chapter
  • First Online:

  • 1751 Accesses

Part of the book series: Springer Specialist Surgery Series ((SPECIALIST))

Thyrotoxicosis represents the clinical syndrome that results from exposure to elevated levels of circulating thyroid hormones. Hyperthyroidism is used to describe thyrotoxicosis resulting from overproduction of thyroid hormones by thyrocytes, with Graves’ disease the commonest cause. Less frequently thyrotoxicosis occurs in the absence of hyperthyroidism, for example, a short-term thyrotoxicosis can occur when stored hormones are released in a destructive thyroiditis. The causes of thyrotoxicosis are listed in Table 6.1. Graves’ disease, toxic multinodular goiter, and solitary toxic nodule account for 95% of cases and are commonly encountered in surgical practice. Causes such as Hashimoto’s thyroiditis or drug-related thyrotoxicosis are uncommon but may require surgical evaluation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ronnov-Jessen V, Kirkegarard C. Hyperthyoidism – a disease of old age? BMJ. 1973;1:41–3.

    Article  PubMed  CAS  Google Scholar 

  2. Figge J, Leinung M, Goodman AD, et al. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med. 1994;96:229–34.

    Article  PubMed  CAS  Google Scholar 

  3. Cooper DS, Hyperthyroidism. Lancet. 2003;362:459–68.

    Article  PubMed  CAS  Google Scholar 

  4. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ. 2006;332:1369–73.

    Article  PubMed  Google Scholar 

  5. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Wickham survey. Clin Endocrinol (oxf).1977;7:481–93.

    Article  CAS  Google Scholar 

  6. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489–499.

    Article  PubMed  CAS  Google Scholar 

  7. Tunbridge WM, Vanderpump MP. Population screening for autoimmune thyroid disease. Endocrinol and Metab Clinics North Am. 2000;29:239–53.

    Article  CAS  Google Scholar 

  8. Krassas GE, Wiersiinga W. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol. 2006;154:777–80.

    Article  PubMed  CAS  Google Scholar 

  9. Brix TH, Kyvik KO, Hegedus L. What is the evidence of genetic factors in the etiology of Graves’ disease? A brief review. Thyroid. 1998;8:727–34.

    CAS  Google Scholar 

  10. Gough SC. The genetics of Graves’ disease. Endocrinol Metab Clin North Am. 2000;29;255–66.

    Article  PubMed  CAS  Google Scholar 

  11. Leclere J, Weryha G. Stress and autoimmune endocrine diseases. Horm Res. 1989;31:90–3.

    Article  PubMed  CAS  Google Scholar 

  12. Weiss M, Ingbar SH, Winblad S, Kasper DL. Demonstration of a saturable binding site for thyrotropin in Yesinia enteocolitica. Science. 1983;219:1331–3.

    Article  PubMed  CAS  Google Scholar 

  13. Arscott P, Rosen ED, Koenig RJ, et al. Immunoreactivity to Yesinia enteocolitica antigens in patients with autoimmune thyroid disease. J Clin Endocrinol Metab. 1992;75;295–300.

    Article  PubMed  CAS  Google Scholar 

  14. Zakarija M, McKenzie JM, Eidson MS. Transient neonatal hypothyroidism: characterization of maternal antibodies to the thyrotropin receptor. J Clin Endocrinol Metab. 1990;70:1239–46.

    Article  PubMed  CAS  Google Scholar 

  15. Graves PN, Davies TF. New insights into the thyroid-stimulating hormone receptor, the major antigen of Graves’ disease. Endocrinol Metab Clin North Am. 2000;29:267–86.

    Article  PubMed  CAS  Google Scholar 

  16. Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ opthalmopathy. J Clin Endocrinol Metab. 1998;83:998–1002.

    Article  PubMed  CAS  Google Scholar 

  17. Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated opthalmopathy. Thyroid. 2002;3:193–5.

    Article  Google Scholar 

  18. Prummel MF, Wiersinga WM. Smoking and risk for Graves disease. JAMA. 1993;269:479–82.

    Article  PubMed  CAS  Google Scholar 

  19. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ opthalmopathy. N Eng J Med. 1998;338:73–8.

    Article  CAS  Google Scholar 

  20. Cooper DS. Antithyroid drugs. N Eng J Med. 2005;352:905–17.

    Article  CAS  Google Scholar 

  21. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves hyperthyroidism. Eur J Endocrinol. 2005;153:489–8.

    Article  PubMed  CAS  Google Scholar 

  22. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983;98:26–9.

    PubMed  CAS  Google Scholar 

  23. Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study. Clin Endocrinol. 1998;49:451–7.

    Article  CAS  Google Scholar 

  24. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med. 1990;150:621–4.

    Article  PubMed  CAS  Google Scholar 

  25. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8:222–4.

    PubMed  Google Scholar 

  26. Noh JY, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf). 2001;54:651–4.

    Article  CAS  Google Scholar 

  27. Hamilton J, Lawrence JH. Recent clinical developments in the therapeutic application of raio-posphorus and radioiodine. J Clin Invest. 1942;624:1942.

    Google Scholar 

  28. Reeve TS. Surgical treatment for thyrotoxicosis. Br J Surg. 1988;75:833–4.

    Article  PubMed  CAS  Google Scholar 

  29. Torring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81:2986–93.

    Article  PubMed  CAS  Google Scholar 

  30. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab. 1990;70:1518–24.

    Article  PubMed  CAS  Google Scholar 

  31. Nagayama Y, Izumi M, Nagataki S. The management of hyperthyroidism due to Graves' disease in Japan in 1988. The Japan Thyroid Association. Endocrinol Jpn. 1989;36:299–314.

    PubMed  CAS  Google Scholar 

  32. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves’ disease in Europe in 1986. Results of an international survey. Acta Endocrinol Suppl (Copenh). 1987;285:3–23.

    CAS  Google Scholar 

  33. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.

    Article  PubMed  CAS  Google Scholar 

  34. Santos RB, Romaldidi JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves disease. Thyroid. 2004;14:525–30.

    Article  PubMed  CAS  Google Scholar 

  35. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514–7

    Article  PubMed  CAS  Google Scholar 

  36. Iagaru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med. 2007;48:379–89.

    PubMed  CAS  Google Scholar 

  37. Kraimps JL, Bouin-Pineau MH, Marechaud R, Barbier J. Thyroid nodules associated with Graves' disease: another argument for surgical treatment. Chirurgie. 1997;122:488–90.

    PubMed  CAS  Google Scholar 

  38. Chang DC, Wheeler MH, Woodcock JP, et al. The effect of preoperative Lugol’s iodine on thyroid blood flow in patients with Graves’ hyperthyroidism. Surgery. 1987;102:1055–61.

    PubMed  CAS  Google Scholar 

  39. Davison S, Lennard TW, Davison J, Kendall-Taylor P, Perros P. Management of a pregnant patient with Graves’ disease complicated by thionamide-induced neutropenia in the first trimester. Clin Endocrinol (Oxf). 2001;54:559–61.

    Article  CAS  Google Scholar 

  40. Klementschitsch P, Shen KL, Kaplan EL. Reemergence of thyroidectomy as treatment for Graves’ disease. Surg Clin North Am. 1979;59:35–44.

    PubMed  CAS  Google Scholar 

  41. Palit TK, Miller CC, Milenburg DM. The efficacy of thyroidectomy for Graves disease: a meta-analysis. J Surg Res. 2000;90:161–5.

    Article  PubMed  CAS  Google Scholar 

  42. Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery. 1996;120:1020–25.

    Article  PubMed  CAS  Google Scholar 

  43. Hermann M, Roka R, Freissmuth M. Early relapse after operation for Graves’ disease: postoperative hormone kinetics and outcome after subtotal, near-total, and total thyroidectomy. Surgery. 1998;124:894–900.

    Article  PubMed  CAS  Google Scholar 

  44. Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for the surgical management of Graves' disease? Thyroid. 2005;15: 569–74.

    Article  PubMed  Google Scholar 

  45. Sugino K, Minura T, Ozaki O, et al. Early recurrence of hyperthyroidism in patients with Graves’ disease treated by subtotal thyroidectomy. World J Surg. 1995;19:648–52.

    Article  PubMed  CAS  Google Scholar 

  46. Melliere D, Etienne G, Becquemin J-P. Operation for hyperthyroidism: methods and rationale. Am J Surg. 1988;155:395–9.

    Article  PubMed  CAS  Google Scholar 

  47. Hedley AJ, Brewsher PD, Jones SJ, et al. Late onset hypothyroidism after subtotal thyroidectomy for hyperthyroidism: implications for long term follow-up. Br J Surg. 1983;70:740–3.

    Article  PubMed  CAS  Google Scholar 

  48. Linos DA, Karakitsos D, Papademetriou J. Should the primary treatment of hyperthyroidism be surgical? Eur J Surg. 1997;163:651–7.

    PubMed  CAS  Google Scholar 

  49. England RJ, Atkin S. Total thyroidectomy is best operation for thyrotoxicosis. BMJ. 2007;334:710 (letter).

    Article  PubMed  Google Scholar 

  50. Takamura Y, Nakano K, Uruno T, et al. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal Thyroidectomy. Endocr J. 2003;50(5):595–601.

    Article  PubMed  Google Scholar 

  51. Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goitre with hyperthyroidism (Plummers disease): surgery versus radioiodine. Surgery. 2002;132:916–23.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes and Endocrinology, St. Thomas’ Hospital, St. Thomas, London, UK

    Johnathan G.H. Hubbard & Paul V. Carroll (MD)

Authors
  1. Johnathan G.H. Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul V. Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Thomas Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom

    Johnathan Hubbard

  2. Coll Physicians & Surgeons Columbia, Fort Washington Avenue 161, New York, 10032, U.S.A.

    William B. Inabnet

  3. Queen Mary Hospital, University of Hong Kong Medical Centre, Pokfulam, Hong Kong, China, People's Republic

    Chung-Yau Lo

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Hubbard, J.G., Carroll, P.V. (2009). Thyrotoxicosis and Thyroiditis: Causes, Investigation, and Management. In: Hubbard, J., Inabnet, W., Lo, CY. (eds) Endocrine Surgery. Springer Specialist Surgery Series. Springer, London. https://doi.org/10.1007/978-1-84628-881-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-881-4_6

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-880-7

  • Online ISBN: 978-1-84628-881-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation